New trial tests stimulant and exercise to fight cancer fatigue
NCT ID NCT03525873
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This phase III trial tests whether a combination of methylphenidate (a stimulant drug) and physical activity can reduce cancer-related fatigue in 212 patients with metastatic cancer who are receiving anti-PD1 immunotherapy. Participants will be randomly assigned to receive either methylphenidate plus physical activity or a placebo plus physical activity. The study measures changes in fatigue scores and daily activity levels over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
methylphenidate (a central nervous system stimulant) and physical activity (aerobic and resistance exercises)
What this could lead to
If it works, this could offer a way to ease severe fatigue for people with advanced cancer on immunotherapy, improving their daily quality of life.
What could go wrong
This is a phase III trial, but fatigue is subjective and hard to measure. The drug may cause side effects like insomnia or anxiety, and the exercise program may be difficult for very ill patients to follow.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.